AM3101 - Meniscus Repair
Meniscus Tears & Amplicore's Solution
Meniscus tears are among the most common knee injuries. Athletes, particularly those who play contact sports, are at risk for meniscus tears. Currently, only operative treatments are considered clinically appropriate to treat these injuries. However, the majority of the meniscus is avascular in structure (characterized by a lack of blood vessels), and successful repair that results in consistent healing cannot always be achieved. Unfortunately, the failure rate for treatment is close to 25%. Furthermore, if damaged meniscus is left untreated, post-trauma osteoarthritis (PTOA) will develop, leading to an unstable knee. At present, no therapeutic agents have been developed to facilitate meniscal repair. AM3101 fills this gap!
U.S. Military Interests in AM3101
Knee injuries are also common in both military combat and basic training. While nearly 1 in 4 Americans suffers from symptoms associated with OA, musculoskeletal disorders affect more than 1 in 3 who have served in the military. Military members 40 years or older are twice as likely to develop arthritis after returning to civilian life, and OA rates in active-duty personnel 20 years or younger are 26 percent higher than those of their nonmilitary peers. Currently, surgical repair is the only solution for torn meniscus.
Because AM3101 has shown promise in facilitating meniscal healing, the U.S. military has been keenly interested in our technology as a regenerative approach to managing soft tissue injury. Amplicore is currently co-leading an effort with the University of Cincinnati to conduct an early phase clinical trial funded by the Department of Defense (DoD) to evaluate the safety and efficacy of AM3101 as an adjuvant therapy for meniscus repair.